Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
about
Cardiotoxicity in childhood cancer survivors: strategies for prevention and managementRenal tumours: long-term outcomeSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specificSinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven?Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivoDoxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicityA novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivoExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cardiac complications of chemotherapy: role of imaging.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography.Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.Cardiac damage after treatment of childhood cancer: a long-term follow-up.Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.Anthracyclines and the heart.Anthracyclines: cardiotoxicity and its prevention.Late effects of treatment for wilms tumorCardiotoxicity of cancer therapy.A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.A method for detection of doxorubicin-induced cardiotoxicity: Flow-mediated vasodilation of the brachial artery.Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivorsAnticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts)Doxorubicin-induced cardiotoxicity in adult Indian patients on chemotherapy.Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction.Treating cancer patients. Practical monitoring and management of therapy-related complications.Chemotherapy in Ewing's sarcoma.Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic moleculeExercise training in childhood cancer survivors with subclinical cardiomyopathy who were treated with anthracyclinesVascular injury in cancer survivors.Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patientsPotential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.Recent advances in breast cancer radiotherapy: Evolution or revolution, or how to decrease cardiac toxicity?Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain.Thymol and Carvacrol Prevent Doxorubicin-Induced Cardiotoxicity by Abrogation of Oxidative Stress, Inflammation, and Apoptosis in Rats.
P2860
Q24628695-7D309773-F735-4CF7-98E2-74E5995B6F70Q26828577-0404A4C9-D25F-426A-BCB6-AC5B2BB52F2EQ27007849-D25615F4-C8CA-4004-96FE-98F002A54BDBQ27027354-2245DF8C-8190-48D1-93A4-BB14DA531DFAQ27301261-E8EB616F-FE2F-4735-80AA-3DA62F813E3BQ28179461-F3CEBE07-12B5-46AB-A8A4-8FCA16038CB1Q28258783-323F4B74-7C8D-437C-8417-C9CE2109844BQ28306329-962E6FD9-6E78-44BC-AD39-042E7B3011F8Q28541985-A4C853CE-4850-42AD-8098-5B1B1D549EF6Q30401812-5A9F9BD0-2272-4455-8A8F-0F49B14E2A7DQ30415201-6FB3A094-E9C5-4C2C-9A8F-00E07C209E86Q30427656-7F1E6A28-F62C-424A-A600-6FD4416AC1A5Q30439608-A5CC50FE-4B61-4885-AE0E-941F7E411892Q30491590-25354E80-8568-4A9B-8B6F-06B94C685DB1Q33214690-C08566AF-DF33-4A75-B5AC-E4A940652782Q33336217-012F51C3-6FA8-4FA7-869D-AC5A1CD8A345Q33613318-6898BD54-6510-4D02-8522-072B515542BAQ33613628-C44CA222-E8CA-45E8-B5D7-A3AD061223E9Q33625243-063A48E4-FEB2-4FAC-B8CD-7E14B8B6E374Q33691101-D2758403-ECB5-46EB-B9B2-7E06031A5A72Q33704056-8B76D6DE-6891-4200-BA56-EA4ED7F219C5Q33735167-AE751435-C9CF-4020-89B4-87C8A5524244Q33807892-47CABD08-3EDD-4711-823C-531ABC58AC39Q33831903-0E20D7C6-A39B-49DD-AE67-17E8C7D66DA8Q33948488-B3CFF7A5-E543-45AC-90FC-0A27F64F0862Q33974943-877AE209-3A0D-4201-9B2C-724731A94C18Q33985488-72BAE0F5-59C3-40A4-8056-B256040696CFQ34092826-7B883343-8915-4DF3-8CE3-1D5A8CB75C9BQ34121459-B642C815-D46E-43D2-AB1C-2C829319D0FDQ34164686-404F8B85-4C55-4F6D-ACCA-6EE2958E9EC4Q34173426-3B47E8E6-DF63-4CB6-B6D7-D076837F054DQ34205317-51689A81-3E20-494A-88CD-393E545834DEQ34211238-8B5792AC-F5E5-4BAE-AF25-8B0949E1464EQ34253158-2BB9C5D1-FF5F-424C-8D48-4BE47548832CQ34333236-954CCD6E-965C-4AFA-A267-E14E335C0807Q34390131-9F2374AE-7AEF-4195-9B4D-605DCC253FC2Q34402813-DCB095A2-DF91-4148-A3D8-DA0D3861A708Q34466688-AE3E9931-8332-4A91-8D95-EA76120C098DQ34468934-07BB1932-D74E-479C-AE7C-FFFDEAD2FF6EQ34494900-1FFD7486-2007-4083-93F6-00DC69AEC4D4
P2860
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
@en
type
label
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
@en
prefLabel
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
@en
P2093
P1476
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
@en
P2093
L J Steinherz
M L Murphy
P G Steinherz
P304
P356
10.1001/JAMA.1991.03470120074036
P407
P577
1991-09-01T00:00:00Z